A survey commissioned by CRO Quintiles has revealed that healthcare payers in the U.S. and U.K. want to play a greater role when it comes to drug development and clinical research.
Based on the findings published in Quintiles' annual "New Health Report," payers in the biopharma industry will want to get the ball rolling sooner to get drugs approved faster. That means early collaboration on new compounds under development, forging pre-competitive alliances and crafting risk-sharing agreements to enhance patient-population targeting, the key findings reveal.
Findings and figures differed slightly between the two countries, which surveyed everyone from patients to biopharma executives. For instance, an overwhelming 93% of U.K. payers believe that risk-sharing agreements would improve the drugmaking and approval process, whereas only 59% of Americans felt the same way. More U.K. payers want to get increasingly involved in Phase I, II and III testing compared with their U.S. counterparts, and U.K. patients are willing to accept greater risks if it means greater benefits from trials.
But as PharmaTimes notes, such improvement measures can come with drawbacks, like higher administrative costs and possible disagreements that could arise when it comes to outlining project goals and expectations.
"Biopharma can take steps today and in the future to mitigate risk at each stage of the development and commercialization process," says Dean Summerfield, Quintiles' VP and managing director with consulting in Europe, in a press release about the survey. "Pre-competitive alliances can assist in accelerating the development of innovative medicines. Working in collaboration with both payers and providers during development can help to ensure that collected data meet their priorities in terms of demonstrating value."